Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. reports company developments as a medical device company focused on epilepsy care through the RNS System, a brain-responsive neuromodulation platform that monitors brain electrical activity and delivers personalized electrical stimulation at the seizure source. Recurring updates cover RNS System revenue, financial results, gross margin, research and development spending, and corporate outlook commentary.
NeuroPace news also includes clinical evidence for drug-resistant focal epilepsy and broader epilepsy programs, including post-approval study publications and NAUTILUS trial presentations. Additional announcements include healthcare conference presentations, investor communications, product-platform development, AI-enabled tools, and other clinical or regulatory disclosures tied to responsive neurostimulation.
NeuroPace (Nasdaq: NPCE) will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting in Cleveland, Ohio, from May 29 – June 2, 2026.
The company will showcase responsive neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, thalamic neuromodulation, and its FDA-approved AI tool ECoG Assistant.
NeuroPace (Nasdaq: NPCE) received FDA approval for ECoG Assistant, its first AI-driven, clinician-enabled feature for RNS therapy. Built on long-term intracranial EEG data, it helps identify ECoGs of Interest and supports faster treatment decisions. A next-generation, cloud-based PDMS is also under FDA review, with expected approval in Q2 2026.
NeuroPace (Nasdaq: NPCE) reported Q1 2026 revenue of $22.1 million, including $0.1 million from DIXI Medical. Non-GAAP revenue excluding DIXI grew 20.1% year over year to $22.0 million, with RNS System revenue of $21.7 million, up 19.5%.
GAAP net loss was ($6.7) million; non-GAAP net loss was ($4.4) million. The company raised 2026 revenue guidance to $99–$101 million, assumes 21–23% RNS growth, and modestly improved Adjusted EBITDA guidance to a loss of ($8.5)–($9.5) million.
NeuroPace (Nasdaq: NPCE) will report first quarter 2026 financial results after market close on May 12, 2026.
A live webcast and conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET; telephone participation is available with Conference ID 8467256. The webcast will be archived on the investor site and replayable for at least 90 days.
NeuroPace (NASDAQ: NPCE) reported publication of 3-year Post-Approval Study results showing an 82% median seizure reduction in drug-resistant focal epilepsy and presented 12- and 18-month NAUTILUS data at AAN 2026 showing a 77% median reduction in generalized tonic-clonic seizures at 18 months.
NAUTILUS also showed declines in injury events (~30%), a 44% lower benzodiazepine rescue use (p<0.001), and >80% Clinical Global Impression of Change at 18 months.
NeuroPace (Nasdaq: NPCE) said its management will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 1:30pm ET (10:30am PT).
The presentation will be available via live webcast and a replay will remain available for thirty days in the Events & Presentations section of NeuroPace's investor website.
NeuroPace (Nasdaq: NPCE) will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 8:40am PT in Miami, FL. Management will also host investor meetings during the conference.
The presentation will be available via live webcast and a replay will be posted for thirty days in the Events & Presentations section of NeuroPace’s investor website.
NeuroPace (Nasdaq: NPCE) reported Q4 2025 revenue of $26.6M (+24% YoY) and full-year 2025 revenue of $100.0M (+25% YoY). RNS System revenue was $22.4M in Q4 and $81.7M for 2025. Gross margin improved to 77.4% in Q4 and 77.2% for the year.
The company submitted a PMA supplement for IGE, expects potential mid-2026 approval, received higher Medicare reimbursement rates for implants/replacements, and reiterated 2026 guidance with 20–22% core RNS growth and revenue guidance of $98–$100M.
NeuroPace (Nasdaq: NPCE) will report fourth-quarter 2025 financial results after market close on March 3, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors can join via a live webcast or by telephone at +1 (800) 715-9871 (Conference ID 8467256). The webcast will be archived on the company investor relations events page and available for replay for at least 90 days.
NeuroPace (Nasdaq: NPCE) reported preliminary unaudited results for Q4 and FY2025 and gave initial 2026 outlook. FY2025 revenue ~ $100.0M (+25% vs 2024) and Q4 2025 revenue ~ $26.6M (+24% vs Q4 2024). RNS revenue was ~ $81.7M for FY2025 (+25%) and ~ $22.4M for Q4 (+26%). Cash and short-term investments were $61.1M at 12/31/2025. The company expects 2026 revenue $98M–$100M, assuming 20%–22% growth in core RNS revenue and no contribution from IGE, Service revenue, or DIXI. Gross margin is expected at 81%–82% for 2026 versus preliminary 77.2% in 2025. A PMA supplement for an IGE indication was filed; potential approval could follow in the second half of 2026.